Gen-Probe Incorporated
SAN DIEGO, November 30, 2010 - Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company's
PANTHER(TM) system, a fully automated and integrated molecular testing system
designed with the flexibility to handle a wide range of testing needs, has
been CE-marked and is available for sale in Europe.
MANCHESTER, England, November 8, 2010 - Gen-Probe Incorporated (Nasdaq: GPRO) has launched in Europe the
ELUCIGENE(TM) KRAS.BRAF kit, a highly sensitive, single-tube assay designed
for the simultaneous quantitative detection of seven common KRAS mutations
and the V600E BRAF mutation.
SAN DIEGO, August 23, 2010 - Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Prodesse's
ProFAST(TM)+ assay, a molecular test that simultaneously detects and
differentiates three common influenza A virus subtypes - seasonal A/H1,
seasonal A/H3, and 2009 H1N1 - has received its CE (Conformit Europenne)
Mark, enabling it to be commercialized in the European Union.
SAN DIEGO, June 30, 2010 - Gen-Probe Incorporated (Nasdaq: GPRO) announced today that it has
received a European CE mark for its APTIMA(R) assay for Trichomonas
vaginalis, a common parasitic sexually transmitted disease.
SAN DIEGO, April 22, 2010 - -- Data Also Suggest that PCA3 Scores May Indicate Prostate Cancer
Aggressiveness --
Gen-Probe's (Nasdaq: GPRO) PROGENSA(R) PCA3 assay can help predict the
outcome of initial prostate biopsies in men suspected of having prostate
cancer, according to a study of the molecular urine test presented in a
scientific poster last week at the 25th annual European Association of
Urology (EAU) Congress in Barcelona, Spain.
